Can Qsymia be prescribed indefinitely for weight loss if the patient meets the requirements?

Qsymia, a combination medication containing phentermine and topiramate, is approved for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or those with a BMI of 27 kg/m² or greater who also have weight-related comorbidities.

The primary reason Qsymia can be prescribed indefinitely, as long as the patient continues to meet the necessary criteria and is under appropriate medical supervision, is due to its role in managing obesity, a chronic disease. Weight management typically requires ongoing treatment rather than a short-term solution, thus reflecting the chronic nature of obesity.

Additionally, long-term studies have shown that continued use can aid in maintaining weight loss and stabilizing health markers. However, ongoing evaluation of the patient's progress and health status is essential to ensure the benefits of the medication outweigh potential risks or side effects. Regular follow-ups and assessments help guide future treatment and dosage adjustments as needed.